New York, Jan 9, 2026, 05:47 EST — Premarket
- Oscar Health shares were little changed premarket after a Thursday rally tied to Washington policy headlines.
- UBS upgraded the health insurer to neutral, pointing to steadier-than-feared exchange enrollment.
- A filing showed Oscar’s CTO sold shares this week under a pre-set trading plan.
Oscar Health shares were flat at $16.90 in premarket trading on Friday, after rising 2.6% in the prior session, as investors weighed a U.S. House vote to restore expired Affordable Care Act subsidies and fresh analyst commentary.
The subsidies, a form of tax credit that lowers monthly premiums for many people who buy coverage through the ACA marketplaces, are a live wire for insurers like Oscar that sell heavily on the exchanges. They lapsed at the end of 2025, and the sticker shock is already showing up in what consumers pay.
The House measure now heads to the Senate, where talks have centered on a shorter extension and tighter eligibility, Axios reported. The Congressional Budget Office has projected the House-passed version would add roughly $80.6 billion to the deficit over a decade, the report said.
Oscar closed at $16.90 on Thursday after swinging between $16.79 and $17.70, then briefly traded up about 6% after hours, according to market data. Centene and Molina Healthcare, two insurers with meaningful government-program exposure, were up about 2.5% and 4% in premarket trading, while UnitedHealth rose about 1.5%.
UBS analyst Jonathan Yong upgraded Oscar to neutral from sell and lifted his price target to $17 from $12, citing “better-than-expected enrollment” in health insurance exchanges. He wrote that exchange enrollment was “holding up better than feared,” despite the subsidy expiration. Investing.com
Still, a regulatory filing showed Oscar co-founder and President of Technology & CTO Mario Schlosser converted Class B shares and sold 76,962 Class A shares on Jan. 6 for an average $17.01, in a move the filing said was made under a Rule 10b5-1 plan — a pre-arranged trading program that sets transactions in advance.
The risk for bulls is that Washington delivers something messier than the market wants: a shorter patch, new restrictions, or a Senate stall that drags the issue into election-year trench fighting. For Oscar, a sharper-than-expected drop in exchange sign-ups would hit growth assumptions, while medical-cost pressure can erase a lot of “policy relief” fast.
Investors’ next checkpoints are Senate negotiations on the subsidy bill and Oscar’s next earnings report, which Nasdaq’s calendar estimates for Feb. 3.
